Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 2, Issue 7, Pages 581-587Publisher
NATURE RESEARCH
DOI: 10.1038/nrd1134
Keywords
-
Ask authors/readers for more resources
The discovery and development of the bicyclam AMD3100 - a chemokine receptor antagonist - has highlighted the therapeutic potential of such compounds in HIV infection, inflammatory diseases, cancer and stem-cell mobilization. Here, I describe the development process of AMD3100, which began about 15 years ago with the isolation of an impurity, and the basis for the clinical application of AMD3100 and its congeners.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
